Genomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study
Vaccines · 31.05.2026 · 14 (6) · 496
DOI: 10.3390/vaccines14060496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 31.05.2026. Verfasst von Amina Al-Jardani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Public Health Laboratory, Center for Disease Control and Prevention, Muscat 100, Oman. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Gulf, Pfizer.
Abstract (Originalsprache)
Background/Objectives: Following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in Oman, this study aimed to characterize the genomic epidemiology, serotype distribution, and antimicrobial resistance (AMR) of Streptococcus pneumoniae causing invasive pneumococcal disease (IPD).
Methods
All IPD isolates collected through national laboratory-based surveillance between 2018 and 2021 were analyzed using Whole-Genome Sequencing (WGS). Bioinformatics tools determined serotypes, multilocus sequence types (MLSTs), and Global Pneumococcal Sequence Clusters (GPSCs). Clinical correlates and predictors of mortality were assessed via multivariate logistic regression.
Results
A total of 129 IPD isolates were included. Serotype 3 (11.6%) was the most prevalent, followed by 23B and 9N (10.8% each), and 8 (8.5%). PCV13 serotypes accounted for only 26.4% of isolates, while PCV20 coverage reached 59.7%. Significant clonal diversity was observed, with GPSC12 (Serotype 3) and GPSC699 (Serotype 9N/13) being prominent lineages. Multidrug resistance (MDR) was identified in 36.4% of isolates, primarily driven by GPSC6 and GPSC699. The case fatality rate was 23.0%. Advanced age (≥65 years) and clinical presentation with bacteremia were significant independent predictors of death, whereas bacterial genotype and AMR status were not.
Conclusions
The findings demonstrate significant serotype replacement in Oman after the introduction of PCV13. The high prevalence of non-vaccine serotypes and emerging MDR clones justifies the transition to higher-valency vaccines like PCV20. Sustained genomic surveillance remains essential to monitor the evolving landscape of invasive pneumococcal lineages.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Central Public Health Laboratory, Center for Disease Control and Prevention, Muscat 100, Oman.
- Department of Medical Microbiology, University of Pécs Medical School, 7624 Pécs, Hungary.
- Integrated Surveillance Department, Center for Disease Control and Prevention, Muscat 100, Oman.
- Association of Public Health Laboratories, Muscat 117, Oman.
- Infectious Diseases Unit, Department of Medicine, Royal Hospital, Muscat 111, Oman.
ORCID-Profile: Amina Al-Jardani, Mohamed Al-Bulushi, Adil Al-Wahaibi, Rajesh Kumar, Seif Al-Abri
Förderung
- Pfizer Gulf
- Pfizer
Zitieren
APA
Al-Jardani, A., Al-Kharusi, N., Al-Bulushi, M., Al-Wahaibi, A., Al-Shekaili, N., Al-Fahdi, S., Kumar, R., Al-Abri, S., & Al-Rashdi, A. (2026). Genomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study. Vaccines, 14(6), 496. https://doi.org/10.3390/vaccines14060496
Vancouver
Al-Jardani A, Al-Kharusi N, Al-Bulushi M, Al-Wahaibi A, Al-Shekaili N, Al-Fahdi S, et al. Genomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study. Vaccines. 2026;14(6):496. doi:10.3390/vaccines14060496
BibTeX
@article{AlJardani2026,
author = {Al-Jardani, Amina and Al-Kharusi, Najma and Al-Bulushi, Mohamed and Al-Wahaibi, Adil and Al-Shekaili, Neima and Al-Fahdi, Suad and Kumar, Rajesh and Al-Abri, Seif and Al-Rashdi, Azza},
title = {Genomic Characterization and Predictors of Mortality in Invasive Streptococcus pneumoniae Disease in Oman: A Four-Year National Genomic Study},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {6},
pages = {496},
doi = {10.3390/vaccines14060496}
}
EUVIMED